DK3102232T3 - Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst - Google Patents
Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst Download PDFInfo
- Publication number
- DK3102232T3 DK3102232T3 DK15746033.8T DK15746033T DK3102232T3 DK 3102232 T3 DK3102232 T3 DK 3102232T3 DK 15746033 T DK15746033 T DK 15746033T DK 3102232 T3 DK3102232 T3 DK 3102232T3
- Authority
- DK
- Denmark
- Prior art keywords
- abnorm
- compositions
- treating
- methods
- cell growth
- Prior art date
Links
- 230000010261 cell growth Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461937253P | 2014-02-07 | 2014-02-07 | |
| PCT/US2015/014843 WO2015120289A1 (en) | 2014-02-07 | 2015-02-06 | Methods and compositions for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3102232T3 true DK3102232T3 (da) | 2020-04-20 |
Family
ID=53778481
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15746033.8T DK3102232T3 (da) | 2014-02-07 | 2015-02-06 | Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst |
| DK20154659.5T DK3698790T3 (da) | 2014-02-07 | 2015-02-06 | Fremgangsmåder til behandling af abnorm cellevækst |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20154659.5T DK3698790T3 (da) | 2014-02-07 | 2015-02-06 | Fremgangsmåder til behandling af abnorm cellevækst |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9962385B2 (https=) |
| EP (2) | EP3698790B1 (https=) |
| JP (3) | JP2017505321A (https=) |
| DK (2) | DK3102232T3 (https=) |
| ES (2) | ES2779975T3 (https=) |
| FI (1) | FI3698790T3 (https=) |
| WO (1) | WO2015120289A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201805890QA (en) * | 2014-01-09 | 2018-08-30 | Verastem Inc | Compositions and methods for treatment of abnormal cell growth |
| JP2018519327A (ja) | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| WO2018148666A1 (en) * | 2017-02-13 | 2018-08-16 | University Of Pittsburgh-Of The Commonwealth Systems Of Higher Education | Focal adhesion kinase inhibitor as a therapeutic agent in diabetes |
| IL257225A (en) * | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
| JP2022525616A (ja) * | 2019-03-19 | 2022-05-18 | ユン，キュソン | 細胞サンプルの評価のための方法およびシステム |
| WO2020236620A1 (en) * | 2019-05-17 | 2020-11-26 | Memorial Sloan Kettering Cancer Center | Methods for predicting responsiveness of cancer to ferroptosis-inducing therapies |
| US12521394B2 (en) | 2019-06-21 | 2026-01-13 | Pattern Computer, Inc. | Therapeutic compositions and methods for treating cancers |
| WO2021047783A1 (en) | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| AU2020388848A1 (en) * | 2019-11-18 | 2022-05-26 | Inxmed (Nanjing) Co., Ltd. | Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation |
| US11666574B2 (en) * | 2019-11-27 | 2023-06-06 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| JP7582694B2 (ja) | 2020-01-10 | 2024-11-13 | イミューニヤリング コーポレーション | Ｍｅｋ阻害剤及びその治療的使用 |
| CN115279376A (zh) * | 2020-01-31 | 2022-11-01 | 维瑞斯特姆股份有限公司 | 用于治疗异常细胞生长的组合疗法 |
| MX2022009612A (es) | 2020-02-05 | 2022-09-19 | Inxmed Nanjing Co Ltd | Combinacion de bi853520 con farmacos quimioterapeuticos. |
| EP4288057A4 (en) * | 2021-02-05 | 2025-03-12 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| TW202313044A (zh) | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0810411B8 (pt) | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| KR101489045B1 (ko) * | 2009-10-12 | 2015-02-02 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제자 및 ｍｅｋ 억제자의 조합 |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| AR084216A1 (es) | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| WO2013170066A1 (en) * | 2012-05-09 | 2013-11-14 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Peptides for the treatment of cancer |
| WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| KR20150067323A (ko) | 2012-10-12 | 2015-06-17 | 글락소스미스클라인 엘엘씨 | 조합물 |
-
2015
- 2015-02-06 ES ES15746033T patent/ES2779975T3/es active Active
- 2015-02-06 ES ES20154659T patent/ES2945387T3/es active Active
- 2015-02-06 WO PCT/US2015/014843 patent/WO2015120289A1/en not_active Ceased
- 2015-02-06 FI FIEP20154659.5T patent/FI3698790T3/fi active
- 2015-02-06 EP EP20154659.5A patent/EP3698790B1/en active Active
- 2015-02-06 JP JP2016550218A patent/JP2017505321A/ja not_active Withdrawn
- 2015-02-06 DK DK15746033.8T patent/DK3102232T3/da active
- 2015-02-06 US US15/116,712 patent/US9962385B2/en active Active
- 2015-02-06 EP EP15746033.8A patent/EP3102232B1/en active Active
- 2015-02-06 DK DK20154659.5T patent/DK3698790T3/da active
-
2018
- 2018-04-02 US US15/943,229 patent/US10406158B2/en active Active
-
2019
- 2019-07-23 US US16/519,605 patent/US20200147080A1/en not_active Abandoned
-
2020
- 2020-03-02 JP JP2020034703A patent/JP7289807B2/ja active Active
-
2022
- 2022-06-17 JP JP2022098159A patent/JP7578643B2/ja active Active
- 2022-11-17 US US17/989,006 patent/US20230321097A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7289807B2 (ja) | 2023-06-12 |
| US20190046531A1 (en) | 2019-02-14 |
| EP3698790A1 (en) | 2020-08-26 |
| EP3102232A1 (en) | 2016-12-14 |
| EP3102232B1 (en) | 2020-02-05 |
| US20160346282A1 (en) | 2016-12-01 |
| US20200147080A1 (en) | 2020-05-14 |
| ES2945387T3 (es) | 2023-06-30 |
| US9962385B2 (en) | 2018-05-08 |
| FI3698790T3 (fi) | 2023-06-06 |
| US20230321097A1 (en) | 2023-10-12 |
| EP3698790B1 (en) | 2023-04-05 |
| ES2779975T3 (es) | 2020-08-21 |
| DK3698790T3 (da) | 2023-06-19 |
| JP7578643B2 (ja) | 2024-11-06 |
| WO2015120289A1 (en) | 2015-08-13 |
| JP2022113886A (ja) | 2022-08-04 |
| HK1232152A1 (en) | 2018-01-05 |
| JP2017505321A (ja) | 2017-02-16 |
| JP2020079320A (ja) | 2020-05-28 |
| US10406158B2 (en) | 2019-09-10 |
| EP3102232A4 (en) | 2017-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3102232T3 (da) | Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst | |
| DK3125927T3 (da) | Fremgangsmåder og sammensætninger til immunmodulering | |
| DK3137605T3 (da) | Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
| DK3206497T3 (da) | Sammensætninger og fremgangsmåder til behandling af meibomsk kirtel-dysfunktion | |
| DK3245225T3 (da) | Sammensætninger og fremgangsmåder til behandling og detektering af cancere | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| DK3092256T3 (da) | Forbindelser og sammensætninger til immunterapi | |
| DK3224603T3 (da) | Nordning og fremgangsmåde til materialekarakteristik | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3215601T3 (da) | Fremgangsmåder til transduktion og celleforarbejdning | |
| DK3134149T3 (da) | Mikrokanyler og fremgangsmåder til fremstilling deraf | |
| DK3137125T3 (da) | Implantat dannet af strukturelt porøst biomateriale og fremgangsmåde til fremstilling af samme | |
| PT3212225T (pt) | Métodos e composições para células t modificadas | |
| DK3161124T3 (da) | Endofytter, associerede sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3108009T3 (da) | Fremgangsmåder og sammensætninger til DNA-profilering | |
| DK2924093T3 (da) | Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse | |
| DK3368663T3 (da) | Virusfri cellelinjer og fremgangsmåder til opnåelse deraf | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
| DK3371313T3 (da) | Fremgangsmåder og sammensætninger til forbedret plantetransformation | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom |